MDXH vs. FLGT, LAB, TALK, BFLY, TBRG, OM, HCAT, SOPH, NYXH, and KRMD
Should you be buying MDxHealth stock or one of its competitors? The main competitors of MDxHealth include Fulgent Genetics (FLGT), Standard BioTools (LAB), Talkspace (TALK), Butterfly Network (BFLY), TruBridge (TBRG), Outset Medical (OM), Health Catalyst (HCAT), SOPHiA GENETICS (SOPH), Nyxoah (NYXH), and KORU Medical Systems (KRMD). These companies are all part of the "medical info sys" industry.
MDxHealth vs. Its Competitors
Fulgent Genetics (NASDAQ:FLGT) and MDxHealth (NASDAQ:MDXH) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment.
In the previous week, Fulgent Genetics had 1 more articles in the media than MDxHealth. MarketBeat recorded 4 mentions for Fulgent Genetics and 3 mentions for MDxHealth. Fulgent Genetics' average media sentiment score of 1.86 beat MDxHealth's score of 1.18 indicating that Fulgent Genetics is being referred to more favorably in the media.
Fulgent Genetics presently has a consensus target price of $25.33, suggesting a potential upside of 15.47%. MDxHealth has a consensus target price of $7.00, suggesting a potential upside of 84.21%. Given MDxHealth's stronger consensus rating and higher possible upside, analysts plainly believe MDxHealth is more favorable than Fulgent Genetics.
Fulgent Genetics has a net margin of -16.83% compared to MDxHealth's net margin of -34.98%. Fulgent Genetics' return on equity of -2.26% beat MDxHealth's return on equity.
Fulgent Genetics has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500. Comparatively, MDxHealth has a beta of 1.49, suggesting that its share price is 49% more volatile than the S&P 500.
MDxHealth has lower revenue, but higher earnings than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.
48.1% of Fulgent Genetics shares are owned by institutional investors. 33.1% of Fulgent Genetics shares are owned by insiders. Comparatively, 1.7% of MDxHealth shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
Fulgent Genetics beats MDxHealth on 9 of the 16 factors compared between the two stocks.
Get MDxHealth News Delivered to You Automatically
Sign up to receive the latest news and ratings for MDXH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MDXH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MDxHealth Competitors List
Related Companies and Tools
This page (NASDAQ:MDXH) was last updated on 9/17/2025 by MarketBeat.com Staff
Free MDXH Stock Alerts